H. pylori eradication rates are declining. Is inadequate acid suppression to blame? 1,3-5
Discover 4 unmet needs in H. pylori
H. pylori infection is common. So is treatment failure.1,5
It is estimated that 1 in 4 patients is failing initial therapy. In the SOARD (Study of Acid-Related Disorders, Perspectives From Physicians and Patients)*, more than 1 in 3 patients needed a 2nd or 3rd line of H. pylori treatment.1,5-7
Learn why treatments fail and what you may
be able to do about it with Dr John Kao.
Hear more about persistent H. pylori infection
in the pHireside CHATS podcast with
Dr Michael Vaezi and Dr Hashem El-Serag.
Inadequate acid suppression can contribute to treatment failure.3
H. pylori bacteria are most susceptible to eradication at pH
levels 6-8. This pH range also helps maximize antibiotic effectiveness and stability. In the absence of adequate acid suppression, H. pylori bacteria may persist despite exposure to antibiotics.3
Get new perspectives on treatment
challenges from Dr William Chey.
Discover the critical role of acid suppression
with Dr Brooks D. Cash.
Complicated dosing schedules can make adherence difficult.3,8
Pill burden and confusing dosing schedules can contribute to low patient adherence. Most PPIs need to be taken 30-60 minutes before a meal, which can present challenges to patients.3,8-11 Other challenges have also been identified. In the SOARD study,* 40% of patients were not fully adherent to a regimen that included PPIs.7a
- •90% forgot to take their medications at least some of the time
- •74% have failed to complete a course of therapy
- •48% missed a dose at least some of the time due to not understanding instructions
Learn more about H. pylori treatment
challenges in the pHireside CHATS podcast
with Dr Michael Vaezi and Dr David Peura.
aIndicates percentage of patients with a response of 2-5 on a 5-point scale that ranged from (1) “never” to (5) “all of the time” to the question: “How often do you forget to take your medication?”12
Treatment satisfaction was low for patients and doctors.7
In the SOARD study*:
- •71% of HCPs were not completely satisfied with current treatment optionsa
- •57% of patients were not completely satisfied with their current treatmentb
Uncover more treatment insights from the SOARD study with Dr Colin Howden.Jump to Video
aIndicates percentage of physicians with a response of 1-5 on a 7-point scale that ranged from (1) “strongly disagree” to (7) “strongly agree” to the statement: “I am satisfied with the current treatment options for my HP patients.”12
bIndicates percentage of patients with a response of 1-7 on a 10-point scale that ranged from (1) “completely dissatisfied” to (10) “completely satisfied” to the question: “How satisfied are you with your current treatment?”12
*SOARD (Study of Acid-Related Disorders, Perspectives From Physicians and Patients), a Phathom Pharmaceuticals‐sponsored study that surveyed 251 physicians (102 gastroenterologists, 149 primary care physicians) and 77 patients with H. pylori infection with dyspepsia between November 2020 and April 2021. The survey captured physician and patient perspectives on symptoms, burden of disease, treatment goals, adherence, and satisfaction. A medical chart review was conducted for all patients. The differences in physician perception and patient experience of the disease have been analyzed as well as patient demographics, clinical characteristics, and disease and treatment management.
Hear from H. pylori experts
New thinking on acid suppression
Learn about the important role acid suppression plays in H. pylori eradication from Dr Brooks D. Cash.
- •Acid suppression contributes to your treatment’s success. Potent and durable acid suppression can help keep pH at levels that maximize effectiveness of the growth-dependent antibiotics used to treat H. pylori infection3,4
- •In our video presentation Unmet needs and the role of acid suppression in the treatment of H. pylori infection, Dr Brooks D. Cash takes us through a clinical overview, current guidelines, and the role acid suppression plays in H. pylori eradication
What can happen when H. pylori is not eradicated?3,4
Discover more about the potential long-term implications of H. pylori infection from Dr Michael Vaezi and Dr Hashem El-Serag.
- •Patients with persistent H. pylori infection may develop serious complications1,2
- •Listen to an episode of the pHireside CHATS podcast series: Persistent H. pylori infection—long-term implications
Acid matters in H. pylori eradication
Hear why acid suppression is a key factor in H. pylori eradication with Dr Michael Vaezi and Dr David Peura.
- •H. pylori eradication rates are declining. There are several contributing factors to take into consideration. One is inadequate acid suppression1,3,5
- •Listen to an episode of the pHireside CHATS podcast series: Eradication failure in H. pylori infection—is acid control a key factor?
Uncover HCP and patient perspectives on the management of H. pylori
Get insights from a recent study on acid-related disorders from Dr Colin Howden.
- •A Phathom Pharmaceuticals–sponsored online survey captured perspectives on H. pylori from patients and physicians
- •Watch as Dr Colin Howden discusses the findings in Acid matters: the study of acid-related disorders (SOARD)*
Acid matters: perspectives on treatment
challenges in H. pylori infection
Dr William Chey discusses his strategy on eradication.
- •It’s not just about antibiotics—acid matters. Learn about the role acid suppression plays in H. pylori eradication3,4
- •Hear what Dr William Chey has to say in his video presentation
Can optimizing acid suppression help support
H. pylori eradication?
Learn about optimizing eradication therapy in your practice from Dr John Yung-Chong Kao.
- •Roughly 1 in 5 patients fails first-line H. pylori therapy.1,5 Join Dr Kao as he examines why and discusses strategies to optimize eradication
- •Watch Acid matters: perspectives on optimizing eradication therapy in the contemporary clinical H. pylori landscape
Uncover unmet needs
hear from experts
in erosive esophagitis
- 1.Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 112(2):212-239. doi:10.1038/ajg.201.563
- 2.Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136(2):487-490. doi: 10.1002/ijc.28999
- 3.Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori Infection: expert review. Gastroenterology. 160(5):1831-1841. doi: 10.1053/j.gastro.2020.11.059
- 4.Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res. 20;5:F10Faculty Rev-17. doi: 10.12688/f1000research.8598.1
- 5.Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, Resnick MB, Moss SF. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019;64(10):2893-2898. doi: 10.1007/s10620-019-05694-4
- 6.Mertz A, Manish S, Pak K, et al. Helicobacter pylori treatment eradication rates in department of defense patients from 2016-2018. Am J Gastroenterol. 2020:S1319. doi: 10.14309/ajg.0000000000000862.
- 7.Howden CW, Spechler SJ, Vaezi MF, et al. Study of acid-related disorders: real-world physician and patient perspectives on burden of Helicobacter pylori infection. Gastro Hep Advances. 2022;1:231-240.
- 8.O’Connor JPA, Taneike I, O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2(5):273-279. doi: 10.1177/1756283X09337342
- 9.Solem C, Mody R, Stephens J, Macahilig C, Gao X. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence. J Am Pharm Assoc (2003). 2014;54(2):144-153. doi: 10.1331/JAPhA.2014.13117
- 10.Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol. 2016;9:163-172. doi: 10.2147/CEG.S91602
- 11.Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21(3):309-319. doi: 10.5056/jnm15105
- 12.Data on file. Phathom Pharmaceuticals, Inc. Florham Park, NJ.